AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02474485 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BVS Absorb implantation.
Description: Absorb bioresorbable vascular scaffold will be implanted to treat in stent restenosis in target vessel.
Study NCT02474485 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DEB Sequent Please inflation.
Description: Inflation of drug eluting balloon Sequent Please will be performed to treat in stent restenosis in target vessel.
Study NCT02474485 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control coronary angiography.
Description: Control coronary angiography will be performed at 9 month follow-up.
Study NCT02474485 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OCT visualization.
Description: OCT visualization will be performed during index procedure and at 9 month follow-up.
Study NCT02474485 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical observation.
Description: Patients will be informed that Investigator will contact them at 12, 24 and 60 months after the procedure. Investigator will collect information regarding clinical status of Patients, cardiac medications and any adverse events that occurred since the last follow-up.
Study NCT03975777 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LO
Description: Participants will perform an acute bout of low-intensity cycling (11 x 1 min intervals at \~73% of peak aerobic work rate interspersed with 1 min recovery periods)
Study NCT03975777 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HI
Description: Participants will perform an acute bout of high-intensity cycling (8 x 1 min intervals at \~100% of peak aerobic work rate interspersed with 1 min recovery periods)
Study NCT03918499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT03918499 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine-based Biologic Agent IRX-2
Description: Given SC
Study NCT03918499 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT04084717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Crizotinib is an orally administered, chemotherapy drug that works by blocking ALK, MET and ROS1 receptor tyrosine kinases from working.~Participants will receive crizotinib, orally (by mouth), at a dose of 250 mg, twice per day, every day of each 28 day cycle.
Study NCT03318588 — intervention group
Intervention type: PROCEDURE
Intervention: Vitrectomy
Description: Pars plana vitrectomy
Study NCT00524277 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GP2 peptide + GM-CSF vaccine
Description: Given intradermally every 3-4 weeks for a total of up to 6 inoculations
Study NCT00524277 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GM-CSF (sargramostim)
Description: GM-CSF given intradermally very 3-4 weeks for a total of up to 6 inoculations
Study NCT00524277 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AE37 + GM-CSF vaccine
Description: Given intradermally every 3-4 weeks for a total of up to 6 inoculations
Study NCT00524277 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GM-CSF (sargramostim)
Description: Given intradermally every 3-4 weeks for a total of up to 6 inoculations
Study NCT02813889 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmarToyGym
Description: We aim to develop a SmarToyGym where sensitized, wireless toys are strategically hung and placed within reach of infants to elicit toy-oriented body and arm/hand movements. Each toy will be equipped with sensors capable of measuring the infant's grasping actions such as squeezing, pinching, tilting, etc.~A low-cost 3D motion capture system will be used to collect video data and the infants' reaching and body kinematics in response to the toys. A pressure mat will be used to measure postural changes to detect weight shifts, rolling, crawling and other movements away from the initial posture.
Study NCT00301795 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oblimersen sodium
Description: Given IV
Study NCT00301795 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT00301795 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01119469 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy (CT or ET)
Description: weekly 50-minute sessions for 12 weeks
Study NCT03832348 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET scan imaging
Description: 3 PET scans will be performed after each 3 first infusions of Pembrolizumab
Study NCT01913951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vosaroxin
Description: Given IV over 10 minutes on Day 1 and 4
Study NCT01913951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC or IV over 15 minutes on days 1-7
Study NCT04452630 — intervention group
Intervention type: OTHER
Intervention: Infectious Disease and Cardiology Clinical Consultations
Description: Infectious Diseases and Cardiology Clinical Consultations at 1 month and 12 months of recovery from an episode of Covid-19
Study NCT02071966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Comparison of Ticagrelor with another anti-platelet drug (Clopidogrel)
Study NCT02071966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Comparison of Clopidogrel with another anti-platelet drug (Ticagrelor)
Study NCT03487731 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Human Mesenchymal Stem Cells (hMSCs)
Description: A single administration of 20 million allogeneic mesenchymal stem cell delivered intra-facet via 6 injections of 1.5 mL per injection, total of 9 to 12ml.
Study NCT03487731 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single administration of 1 cc of 1% lidocaine with 1 cc of 2% Ropivicaine and 0.5 cc of betamethasone soluspan (celestone) solution delivered via intra-facet injection.
Study NCT04201665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbetocin
Description: Patients will receive a single dose of carbetocin 100 mcg (Pabal ®) at admission to high dependency obstetric unit after cesarean section.
Study NCT04201665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Patients will receive 5 units of oxytocin ( Syntocinon ®) as a 250 ml 0.9% NaCl infusion at admission to high dependency obstetric unit after cesarean section.
Study NCT03933813 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iron Sucrose
Description: Venofer (Iron Sucrose Injection USP) is a brown, sterile, aqueous, complex of polynuclear iron (III)-hydroxide in sucrose for intravenous use.
Study NCT00389844 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Trainer component of the Exercise Plus Program
Description: With the exception of the routine care group, the exercise trainers visited each of the participant in their homes twice a week for two months, once a week for four months, and once a month for six months.
Study NCT00389844 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Trainer component of the Exercise Plus Program
Description: With the exception of the routine care group, the exercise trainers visited each of the participant in their homes twice a week for two months, once a week for four months, and once a month for six months.
Study NCT00389844 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Plus component (motivation) of the Exercise Plus Program
Description: Motivation only
Study NCT00389844 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Plus component (motivation) of the Exercise Plus Program
Description: Motivation only
Study NCT00389844 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Plus Program (exercise + motivation)
Description: Exercise plus motivation
Study NCT03279029 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood samples
Description: blood samples
Study NCT03279029 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: biopsy
Description: biopsy of aortic valve
Study NCT02428192 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT02428192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02428192 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT01274481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost
Description: patients inhale 20 mcg of Iloprost via nebulizer and, if oxygenation and blood pressure is maintained receive a second dose of 20 mcg of Iloprost 30 minutes later.
Study NCT00527735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab, 10 mg/kg, administered as a single-dose, intravenously (IV), over 90 minutes depending on randomization every 3 weeks (up to 6 doses). Participants could receive additional maintenance ipilimumab at a dose of 10 mg/kg every 12 weeks starting 24 weeks after the first ipilimumab dose.
Study NCT00527735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matched placebo for ipilimumab administered as a single dose IV over 90 minutes every 3 weeks (up to 6 doses) as part of induction. Participants could also receive additional maintenance placebo administered IV over 90 minutes every 12 weeks starting 24 weeks after the first placebo dose.
Study NCT00527735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched placebo for ipilimumab administered as a single dose IV over 90 minutes every 3 weeks (up to 6 doses) as part of induction. Participants could also receive additional maintenance placebo administered IV over 90 minutes every 12 weeks starting 24 weeks after the first placebo dose.
Study NCT02968316 — intervention group
Intervention type: OTHER
Intervention: BIA measurement
Description: observation only
Study NCT00527735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 175 mg/m\^2, administered as a single IV dose over 3 hours every 3 weeks (up to 6 doses). Dose modifications (reductions as well as delays) done as per product label.
Study NCT00527735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m\^2, administered as a single IV dose over 3 hours every 3 weeks (up to 6 doses). Dose modifications (reductions as well as delays) done as per product label.
Study NCT00527735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Area under the concentration curve (AUC)=6, administered as a single IV dose over 30 minutes every 3 weeks (up to 6 doses) as per randomization. Dose modifications (reductions as well as delays) done as per product label.
Study NCT00527735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Area under the concentration curve (AUC)=6, administered as a single IV dose over 30 minutes every 3 weeks (up to 6 doses) as per randomization. Dose modifications (reductions as well as delays) done as per product label.
Study NCT01831167 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dynamic light
Study NCT00723307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: White film-coated tablets, 850mg tablet twice daily, 1.5 years duration
Study NCT00723307 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: White coated tablet; one tablet twice daily; 1.5 years duration
Study NCT00276510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGb 761® (Tanakan®)
Description: 120 mg, 1 tablet twice a day, oral route, during 5 years.
Study NCT00276510 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet twice a day, oral route, during 5 years.
Study NCT02210000 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Camicinal matching placebo is available as tablet to be taken orally with 100mL of water in the morning
Study NCT02210000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camicinal
Description: Camicinal is available as 25 mg tablet to be taken orally with 100mL of water in the morning
Study NCT05343858 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental: Group 1: Spirulina platensis
Description: 16 g/day (two doses of 8g)
Study NCT05343858 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental: Group 2: Chlorella vulgaris
Description: 16 g/day (two doses of 8g)
Study NCT05343858 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Group 3: Control
Description: 16 g/day (two doses of 8g)
Study NCT00205335 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ascencia Breeze Glucose meter
Description: All study participants received glucose meter and test strips.
Study NCT00205335 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Breeze Glucose Monitor (Bayer)
Description: Each participant received a Breeze monitor and glucose test strips.
Study NCT04369378 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation app usage
Description: Investigators will confirm eligibility of applicants, enroll participants in the study and provide an identification number for de-identification of the data, and provide a list of mental health resources to participants. Participants will then be sent a link to a Google Form for the pre-intervention survey, to be completed prior to first use of the mindfulness app. Participants will also be given access to the mindfulness app (Insight Timer), and instructed to use it for 10 min daily for 30 days. Two days before the end of the 30 day intervention period, participants will be sent a link to a Google Form for the post-intervention survey and will be asked to complete the survey within the next 3 days. Two months after the conclusion of the 30 day intervention period, participants will be sent a link to a Google Form for another post-intervention survey, and asked to complete it within 5 days.
Study NCT00194805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth for Diabetes Self Management
Study NCT00194805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth for Diabetes Self Management
Description: Web based education format delivered for a six month period
Study NCT02152826 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Potassium oxalate
Description: Professional application
Study NCT02152826 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Potassium oxalate
Description: Professional application
Study NCT02723812 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GCFLU® Influenza vaccine (Split virion, Inactivated)
Study NCT03633344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbowhite
Study NCT03633344 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carbowhite placebo
Study NCT03795116 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LED-RL phototherapy
Description: The LED-RL treatment device has a 4.7 cm x 6.1 cm rectangular array of LEDs and emits visible red light (633 nm) at a power density of 360.2 W/m2 at room temperature and a distance of 10 mm from the target surface.
Study NCT03795116 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Mock irradiation
Description: The mock therapy device is designed to sound, look, and feel identical to the LED-RL treatment device (i.e., has the same physical components and thermal output), except it does not emit visible red light.
Study NCT02447016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil/emtricitabine/rilpivirine
Study NCT02447016 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil/emtricitabine/efavirenz
Study NCT01794988 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioral Therapy
Description: Each CBT session will last 90 minutes and will teach participants specific skills to better cope with chronic pain. These skills will include breathing exercises, distraction, and relaxation techniques.
Study NCT01794988 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain Education
Description: Subjects will receive mailed educational materials to their homes on a weekly basis. Weekly materials will contain information about the nature of chronic back pain, treatment options, exercises and stretching techniques for maintaining strength and flexibility, and proper protection for a healthy back. Pain education is the standard of care for most outpatient clinics.
Study NCT01794988 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Interactive Voice Response
Description: Therapeutic Interactive Voice Response as a daily self monitoring and relapse prevention tool with didactic reviews and practices of recorded skills and monthly feedback based on daily calls.
Study NCT00817713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Praziquantel, Ivermectin, Albendazole
Description: Standard HIV care plus triple anthelminthic treatment~* Praziquantel 2400mg single dose~* Ivermectin 12 mg, single dose~* Albendazole 400mg, 2 doses in 1 day~All drugs given at baseline, after 6 months and after 12 months.
Study NCT02201615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perineal massage in childbirth
Study NCT02706613 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Face to Face Pulmonary Rehabilitaton
Description: 6 week face to face, incremental exercise and education programme for people with COPD
Study NCT02706613 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Pulmonary Rehab
Description: 6 week online, incremental exercise and education programme for people with COPD
Study NCT00833833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 1 mg, 2 mg, and 5 mg capsules for oral administration packaged in bottles containing a 21-day supply
Study NCT00833833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: oral dexamethasone
Study NCT00833833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: As prophylactic anti-thrombotic treatment, all participants were given aspirin 81-100 mg daily (commercial supply) unless contraindicated. If aspirin was contraindicated, participants were given another form of anti-thrombotic therapy according to hospital guidelines or physician preference.
Study NCT06236659 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Consumption of three different doses of hydrolyzed collagen (HC) with resistance exercise
Description: Each intervention lasts for seven hours and while participants consumed HC, performed resistance exercise and rested, 10 x 5 mL blood samples were collected from a superficial forearm vein using a cannula.~All interventions were performed at the same time of day (08:00 - 15:00).~Different doses of HC (0 grams, 15 grams and 30 grams) and 50 milligrams vitamin C were dissolved with 250 milliliter water in an opaque bottle. To match calories of 30 grams HC, 34.1 grams and 15.4 grams maltodextrin was used in 0 grams HC and 15 grams HC respectively. Also to mask any potential difference in HC doses, 4 grams non-caloric sweetener was used in all HC doses.~The details of dietary supplements used are as follows:~Hydrolysed collagen (Myprotein, Cheshire, UK), Vitamin C powder (Holland and Barrett Retail Limited, Warwickshire, UK), Maltodextrin (Myprotein, Cheshire, UK), and Non-caloric sweetener (Truvia®, SilverSpoon, London, UK)
Study NCT06236659 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Consumption of two different doses of hydrolyzed collagen (HC) with reistance exercise
Description: Each intervention lasts for seven hours and while participants consumed HC, performed resistance exercise and rested, 10 x 5 mL blood samples were collected from a superficial forearm vein using a cannula.~All interventions were performed at the same time of day (08:00 - 15:00).~Different doses of HC (0 grams, and 30 grams) and 50 milligrams vitamin C were dissolved with 250 milliliter water in an opaque bottle. To match calories of 30 grams HC, 34.1 grams and 15.4 grams maltodextrin was used in 0 grams HC and 15 grams HC respectively. Also to mask any potential difference in HC doses, 4 grams non-caloric sweetener was used in all HC doses.~The details of dietary supplements used are as follows:~Hydrolysed collagen (Myprotein, Cheshire, UK), Vitamin C powder (Holland and Barrett Retail Limited, Warwickshire, UK), Maltodextrin (Myprotein, Cheshire, UK), and Non-caloric sweetener (Truvia®, SilverSpoon, London, UK)
Study NCT02751411 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: micro-enema with Promelaxin
Description: The intervention has a lubricating, protective action on the anus and rectum and a balanced osmotic action which elicits the evacuation reflex.
Study NCT02751411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Macrogol 4000
Description: Stool softener
Study NCT03056027 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ecocolordoppler ultrasound testicular evaluation
Description: Ecocolordoppler ultrasound testicular evaluation